MATINS Trial Results Will Be Shared at EADO
Source: Targeted Oncology, April 2022
Results from the melanoma cohort the MATINS trial will be shared at the 18th Congress of the European Association of Dermato-Oncology.
Compelling results from the melanoma cohort in the ongoing phase 1/2 MATINS (Macrophage Antibody to Inhibit Immune Suppression, NCT03733990) trial will be presented at the 18th Congress of the European Association of Dermato-Oncology (EADO) to be held in Seville, Spain, April 21 to April 23, 2022. This announcement comes from a press release by thecoordinators of the trial, Faron Pharmaceuticals Ltd.
The MATINS study is researching bexmarilimab (Clevegen) as a monotherapy treatment. The melanoma cohort within the study is 1 of the 10 advanced treatment-resistant solid tumor types included in part 2 of the study, which consists of 110 patients. Data from 11 melanoma patients, including the cohort of 10 patients in part 2 and 1additional patient with same dosing regimen from part 1, who were refractory to checkpoint inhibition are being presented at the congress.READ THE ORIGINAL FULL ARTICLE